Jubilant Pharmova DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.64×	0.65×	0.85×	0.50×	−4.18×
	0.73×	0.75×	1.22×	0.28×	0.07×
	8.7%	9.9%	11.1%	7.7%	3.5%
	0.59×	0.59×	0.60×	0.59×	0.59×
	2.19×	2.19×	2.04×	2.13×	2.07×
	5.3%	6.2%	14.2%	1.4%	−1.3%
	6.0%	6.0%	14.4%	1.4%	−1.1%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

JUBLPHARMA₹946.00

Jubilant Pharmova Ltd.

· Pharma & Health

₹ CrorePeersGLAND PPLPHARMA KIMS INDGN ONESOURCE GRANULES PFIZER POLYMEDMcap ₹14,947 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	-4.18	0.50	0.85	0.65	0.64
Interest Burden (Pretax/EBIT) ×	0.07	0.28	1.22	0.75	0.73
EBIT Margin %	3.54	7.74	11.13	9.90	8.70
Asset Turnover ×	0.59	0.59	0.60	0.59	0.59
Financial Leverage (Assets/Equity) ×	2.07	2.13	2.04	2.19	2.19
ROE (5-step product, year-end total equity) %	-1.26	1.36	14.18	6.20	5.27
ROE (owners' profit / average owners' equity) %	-1.14	1.42	14.36	5.97	5.97

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.